FDA Approved: OXALIPLATIN — Supplemental Application (Hospira, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Oxaliplatin from Hospira, Inc., under an ANDA. The action updates the regulatory status of this generic cancer drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)

Snippet

SUPPL AP for OXALIPLATIN (OXALIPLATIN)